Denali Therapeutics Stock Performance
| DNLI Stock | USD 19.82 1.02 4.89% |
On a scale of 0 to 100, Denali Therapeutics holds a performance score of 5. The firm shows a Beta (market volatility) of 2.01, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Denali Therapeutics will likely underperform. Please check Denali Therapeutics' potential upside, and the relationship between the sortino ratio and skewness , to make a quick decision on whether Denali Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Denali Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly unfluctuating essential indicators, Denali Therapeutics demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.14) | Five Day Return (5.19) | Year To Date Return 28.09 | Ten Year Return (2.84) | All Time Return (2.84) |
1 | Acquisition by Thornberry Nancy of 17901 shares of Denali Therapeutics at 18.56 subject to Rule 16b-3 | 11/21/2025 |
2 | Denali Therapeutics announces board and leadership changes By Investing.com - Investing.com Nigeria | 11/28/2025 |
3 | Does Denali Therapeutics Discounted Equity Raise Reveal a New Phase in Its Risk Strategy | 12/16/2025 |
4 | Acquisition by Ryan Watts of 236880 shares of Denali Therapeutics at 16.27 subject to Rule 16b-3 | 01/02/2026 |
5 | Acquisition by Schuth Alexander O. of 57700 shares of Denali Therapeutics subject to Rule 16b-3 | 01/05/2026 |
6 | Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome | 01/06/2026 |
7 | Assessing Denali Therapeutics Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review | 01/08/2026 |
8 | Denali Therapeutics Inc. Stock Analysis Exploring An 83 percent Upside Potential - DirectorsTalk Interviews | 01/13/2026 |
9 | 3 Biotech Stocks That Could Double In 2026 - AOL.com | 01/20/2026 |
10 | Acquisition by Klein Peter S of 6037 shares of Denali Therapeutics subject to Rule 16b-3 | 01/28/2026 |
11 | Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcomi... | 01/29/2026 |
12 | Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle Programs at the 2026 WORLDSymposium | 02/02/2026 |
13 | Denali Therapeutics Presents Enzyme TransportVehicle Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium | 02/05/2026 |
14 | Assessing Denali Therapeutics Valuation After WORLDSymposium Clinical Updates And Regulatory Progress | 02/09/2026 |
| Begin Period Cash Flow | 128.7 M | |
| Total Cashflows From Investing Activities | -88.8 M | |
| Free Cash Flow | -363.6 M |
Denali Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,752 in Denali Therapeutics on November 12, 2025 and sell it today you would earn a total of 230.00 from holding Denali Therapeutics or generate 13.13% return on investment over 90 days. Denali Therapeutics is currently generating 0.2727% in daily expected returns and assumes 3.7955% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Denali, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Denali Therapeutics Target Price Odds to finish over Current Price
The tendency of Denali Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 19.82 | 90 days | 19.82 | about 19.57 |
Based on a normal probability distribution, the odds of Denali Therapeutics to move above the current price in 90 days from now is about 19.57 (This Denali Therapeutics probability density function shows the probability of Denali Stock to fall within a particular range of prices over 90 days) .
Denali Therapeutics Price Density |
| Price |
Predictive Modules for Denali Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Denali Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Denali Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Denali Therapeutics is not an exception. The market had few large corrections towards the Denali Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Denali Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Denali Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.40 | |
β | Beta against Dow Jones | 2.01 | |
σ | Overall volatility | 1.89 | |
Ir | Information ratio | 0.12 |
Denali Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Denali Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Denali Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Denali Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (422.77 M) with loss before overhead, payroll, taxes, and interest of (420.66 M). | |
| Denali Therapeutics currently holds about 1.07 B in cash with (347.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66. | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Assessing Denali Therapeutics Valuation After WORLDSymposium Clinical Updates And Regulatory Progress |
Denali Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Denali Stock often depends not only on the future outlook of the current and potential Denali Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Denali Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 164.5 M | |
| Cash And Short Term Investments | 832.3 M |
Denali Therapeutics Fundamentals Growth
Denali Stock prices reflect investors' perceptions of the future prospects and financial health of Denali Therapeutics, and Denali Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Denali Stock performance.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 2.49 B | ||||
| Shares Outstanding | 156.16 M | ||||
| Price To Earning | 60.91 X | ||||
| Price To Book | 3.55 X | ||||
| Price To Sales | 3,644 X | ||||
| Gross Profit | (420.66 M) | ||||
| EBITDA | (492.89 M) | ||||
| Net Income | (422.77 M) | ||||
| Cash And Equivalents | 1.07 B | ||||
| Cash Per Share | 8.66 X | ||||
| Total Debt | 48.71 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.20 X | ||||
| Book Value Per Share | 6.32 X | ||||
| Cash Flow From Operations | (347.69 M) | ||||
| Earnings Per Share | (2.89) X | ||||
| Market Capitalization | 3.25 B | ||||
| Total Asset | 1.37 B | ||||
| Retained Earnings | (1.54 B) | ||||
| Working Capital | 762.23 M | ||||
| Current Asset | 281.74 M | ||||
| Current Liabilities | 10.46 M | ||||
About Denali Therapeutics Performance
By evaluating Denali Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Denali Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Denali Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Denali Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (49.46) | (51.93) | |
| Return On Tangible Assets | (0.28) | (0.29) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.28) | (0.29) | |
| Return On Equity | (0.40) | (0.38) |
Things to note about Denali Therapeutics performance evaluation
Checking the ongoing alerts about Denali Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Denali Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Denali Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (422.77 M) with loss before overhead, payroll, taxes, and interest of (420.66 M). | |
| Denali Therapeutics currently holds about 1.07 B in cash with (347.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66. | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Assessing Denali Therapeutics Valuation After WORLDSymposium Clinical Updates And Regulatory Progress |
- Analyzing Denali Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Denali Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Denali Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Denali Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Denali Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Denali Therapeutics' stock. These opinions can provide insight into Denali Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |